The DOI matches its Crossref record; 18 of the 19 references it cites were found in a registry or an index.
Real‐world treatment patterns, outcomes, resource utilization and costs in treatment‐resistant major depressive disorder: PATTERN, a retrospective cohort study in Belgium
Open accessAbstract
OBJECTIVE: Treatment-resistant depression (TRD), a subgroup of major depressive disorder (MDD) that does not adequately respond to treatment, has a substantial impact on the quality of life of patients and is associated with higher medical and mental health care costs. This study aimed to report real-world treatment patterns, outcomes, resource utilization, and costs in the management of TRD by psychiatrists in Belgium. METHODS: We conducted a retrospective, non-interventional cohort study of patients ≥ 18 years, with diagnosed MDD who are treatment-resistant, defined as not responding to two different antidepressant treatments in the current moderate to severe major depressive episode (MDE). Data obtained from medical records of patients included patient health state (MDE, response, remission, and recovery) and resource use (number of consultations and emergency room visits, non-drug and drug interventions, and hospitalizations). RESULTS: One hundred and twenty-five patients were enrolled in nine sites, with an average observation period of 34 months. During the MDE, 89.7% of patients were treated with selective serotonin reuptake inhibitors, 63.2% with serotonin-norepinephrine reuptake inhibitors, and 60.8% with anti-psychotics. Twenty-four percent of patients did not respond to any treatment; 76% responded, of whom 61% experienced a relapse; 28% of patients reached recovery, of whom 31.4% experienced recurrence. The average yearly direct cost of a TRD patient is €9012, mainly driven by hospitalization in the MDE. The observed absenteeism relates to a high indirect cost, representing 70% of the total MDE cost. CONCLUSION: TRD is associated with a high unmet need and economic burden for patients and society, with highest costs in the MDE health state driven by absenteeism.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Higher indirect costs are also reported in TRD as a consequence of rel atively greater impairment in psychoso cial function, greater need for disability benefits, higher workplace disability and absentee ism, as well as the negative impact on carers 10, 21,24- 35 .”
From Treatment‐resistant depression: definition, prevalence, detection, management, and investigational interventions (2023) · cites this paper as [26]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Scoville, W. B. (1949) · Journal of neurosurgery · doi:10.3171/jns.1949.6.1.0065 · Cited by 7,380
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Nierenberg, A. A., Stewart, J. W., Warden, D., Niederehe, G., Thase, M. E., Lavori, P. W., Lebowitz, B. D., et al. (2006) · American Journal of Psychiatry · doi:10.1176/ajp.2006.163.11.1905 · Cited by 5,643 · cited 2×
“Observational studies in depressed patients report lower remission rates and higher relapse rates for each additional treatment step [8].”
BackgroundResultTreatment-resistant depression: therapeutic trends, challenges, and future directions
Al-harbi (2012) · Patient Preference and Adherence · doi:10.2147/ppa.s29716 · Cited by 796
Bauer, M., Pfennig, A., Severus, E., Whybrow, P. C., Angst, J., Möller, H.-J., & Šon behalf of the Task Force on Unipolar Depressive Disorders (2013) · The World Journal of Biological Psychiatry · doi:10.3109/15622975.2013.804195 · Cited by 632
A Review of the Clinical, Economic, and Societal Burden of Treatment-Resistant Depression: 1996–2013
Mrazek, D. A., Hornberger, J. C., Altar, C. A., & Degtiar, I. (2014) · Psychiatric Services · doi:10.1176/appi.ps.201300059 · Cited by 580 · cited 5×
“These results are comparable to findings from a retrospective cohort study conducted in the UK [27] and international reports on quality of life and costs in function of disease severity and treatment efficacy [9, 10, 28].”
BackgroundResultInfluentialJohnston, K. M., Powell, L. C., Anderson, I. M., Szabo, S., & Cline, S. (2019) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.06.045 · Cited by 321 · cited 3×
“This is aligned with international publications, reporting a substantially higher impact on professional functioning in TRD compared with MDD patients [9, 10, 13].”
BackgroundResultSimon, G. E. (1996) · JAMA · doi:10.1001/jama.275.24.1897 · Cited by 294
Response and remission criteria in major depression – A validation of current practice
Riedel, M., Möller, H.-J., Obermeier, M., Schennach-Wolff, R., Bauer, M., Adli, M., Kronmüller, K., Nickel, T., Brieger, P., Laux, G., et al. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.03.006 · Cited by 288 · cited 1×
“Recovery was defined as an uninterrupted remission for 6 months [17, 18].”
BackgroundSobocki, P., Ekman, M., Ågren, H., Krakau, I., Runeson, B., Mårtensson, B., & Jönsson, B. (2007) · Value in Health · doi:10.1111/j.1524-4733.2006.00162.x · Cited by 157 · cited 1×
“These results are comparable to findings from a retrospective cohort study conducted in the UK [27] and international reports on quality of life and costs in function of disease severity and treatment efficacy [9, 10, 28].”
ResultKubitz, N., Mehra, M., Potluri, R. C., Garg, N., & Cossrow, N. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076882 · Cited by 151 · cited 14×
“Twentyfour percent of patients did not reach response to any therapy during the study period and remained in the MDE health state, confirming the reported unmet need for a subgroup of MDD patients who do not adequately respond to available therapies [7, 23, 25].”
MethodResultInfluential
Research works printed but not linked: 5
- Karakaya G. Evolutie van de prevalentie en de kostprijs van chronische ziektes. Onafhankelijke Ziekenfondsen; 2015.
- Greenwood M. A report on the natural duration of cancer. In: Reports on public health and medical subjects, vol. 33. London: His Majesty’s Stationery Office; 1926. pp. 1–26.
- APA. American Psychiatric Association: Practice Guideline For The Treatment of Patients With Major Depressive Disorder; 2010. 3rd Edition. https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd.pdf Accessed 7 Mar 2021.
- N.I.C.E, National Institute for Health and Clinical Excellence: Guidance, in Depression: The Treatment and Management of Depression in Adults (Updated Edition). Leicester (UK): British Psychological Society; 2010.
- Umbach I, Vanrillaer V. Verblijven in een psychiatrische omgeving. Onafhankelijke Ziekenfondsen; 2014.
Cited by
McIntyre, R. S., Alsuwaidan, M., Baune, B. T., Berk, M., Demyttenaere, K., Goldberg, J. F., Gorwood, P., Ho, R., Kasper, S., Kennedy, S. H., et al. (2023) · World Psychiatry · doi:10.1002/wps.21120 · Cited by 836
Gkesoglou, T., Bargiota, S. I., Iordanidou, E., Vasiliadis, M., Bozikas, V., & Agorastos, A. (2022) · Brain Sciences · doi:10.3390/brainsci12070940 · Cited by 20
“Treatment-resistant depression (TDR) accounts for approximately 30–40% of patients with MDD and is related to a large direct and indirect societal financial burden that represents up to 70% of MDD’s total cost [14].”
BackgroundEconomic evaluation of interventions for treatment-resistant depression: A systematic review
Hannah, L. A., Walsh, C., Jopling, L. A., Pérez, J. M., Cardinal, R. N., & Cameron, R. A. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1056210 · Cited by 16
Pappa, S., Shah, M., Young, S., Anwar, T., & Ming, T. (2024) · BJPsych Open · doi:10.1192/bjo.2023.627 · Cited by 14
“23 The average number of prescriptions per patient was 22 overall, but the number in patients with TRD was twice that in those with MDD.”
ResultThe cost-of-illness and burden-of-disease of treatment-resistant depression in Austria
Walter, E., Traunfellner, M., Gleitsmann, M., Zalesak, M., & Helmenstein, C. (2023) · Journal of Medical Economics · doi:10.1080/13696998.2023.2264718 · Cited by 14
Metadata
- Authors
- Gillain, B., Degraeve, G., Dreesen, T., De Bruecker, G., Buntinx, E., Beke, D., Kestens, C., Valassopoulou, E., Verhelst, F., Peeters, E., Pype, S., De Vos, C., Strens, D., & Vandersmissen, I.
- Affiliations
- Clinique Saint Pierre (BE)
- Alma (BE)
- Centre Hospitalier Régional de Huy (BE)
- Centre hospitalier régional de la Citadelle (BE)
- Grand Charleroi Hospital (BE)
- Janssen (Belgium) (BE)
- Corresponding author
- Vandersmissen, I.
- Venue
- PharmacoEconomics - Open
- Published
- 2021-11-15
- Volume
- 6
- Issue
- 2
- Pages
- 293-302
- ISSN
- 2509-4254 (ISSN-L)
- 2509-4262
- PMC
- PMC8864045
- OpenAlex
- W3211811847
- Cited by
- 16
- References
- 19
- Citations by year
- 2026: 2 · 2025: 2 · 2024: 2 · 2023: 8 · 2022: 1 · 2021: 1
- FWCI
- 1.75
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- creativecommons.org/licenses/by-nc/4.0 (tdm)
- creativecommons.org/licenses/by-nc/4.0 (vor)
- Locations
- PharmacoEconomics - Open (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Keywords
- treatment-resistant depression, major depressive disorder, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, antipsychotic drugs, treatment response and remission, relapse, hospitalization, health care costs, absenteeism, economic burden, Belgium
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Real‐world treatment patterns, outcomes, resource utilization and costs in treatment‐resistant major depressive disorder: PATTERN, a retrospective cohort study in Belgium. https://app.cochat.ai/papers/10.1007/s41669-021-00306-2
- The paper
- Gillain, B., Degraeve, G., Dreesen, T., De Bruecker, G., Buntinx, E., Beke, D., Kestens, C., Valassopoulou, E., Verhelst, F., Peeters, E., Pype, S., De Vos, C., Strens, D., & Vandersmissen, I. (2022). Real‐world treatment patterns, outcomes, resource utilization and costs in treatment‐resistant major depressive disorder: PATTERN, a retrospective cohort study in Belgium. PharmacoEconomics - Open. https://doi.org/10.1007/s41669-021-00306-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.